COMPLICATIONS OF TARE:
RADIATION-INDUCED LIVER DISEASE AND MANAGEMENT
A complete guide to the complications of Y-90 radioembolization โ from common mild post-procedural syndrome through to the serious but preventable risk of radiation-induced liver disease (REILD) โ and how specialist centres prevent, recognise, and manage each.
analyticsAt a Glance
- check_circlePost-embolization syndrome (fatigue, fever, nausea) is common and self-limiting โ resolving within 1โ2 weeks
- check_circleRadiation-induced liver disease (REILD) is the most serious complication โ prevented by personalised dosimetry
- check_circleREILD typically presents 4โ8 weeks post-treatment with jaundice and ascites โ early corticosteroid treatment can prevent progression
- check_circleNon-target embolization (GI ulceration, radiation pneumonitis) is rare when MAA scan workup is correctly performed
Understanding TARE Complications โ A Spectrum From Expected to Serious
TARE complications span a wide spectrum: from the almost universal and self-limiting post-procedural fatigue and fever to the rare but life-threatening radiation-induced liver disease. Understanding this spectrum โ and knowing which symptoms are expected versus which require urgent attention โ is one of the most important things a TARE patient can learn.
โMost TARE side effects are mild and transient. The one serious complication โ REILD โ is largely preventable with personalised dosimetry and recognised early by informed patients and families.โ
Common โ Expected and Self-Limiting
Post-embolization syndrome (fatigue, low-grade fever, nausea, mild right upper quadrant discomfort) occurs in most patients and resolves within 1โ2 weeks without specific treatment. These symptoms reflect the inflammatory response to tumour radiation and partial ischaemia โ they are a sign the treatment is working, not that something is wrong.
Serious โ Rare but Preventable
Radiation-induced liver disease (REILD) and radiation pneumonitis are the most serious complications โ both dose-dependent and largely preventable when pre-treatment workup (MAA scan, lung shunt fraction) and personalised dosimetry are performed correctly. Recognising them early is critical to preventing irreversible damage.
TARE Complications โ Complete Reference
A structured reference of all recognised TARE complications โ organised by frequency, timing, and management approach.
| Complication | Frequency | Timing | Severity | Management |
|---|---|---|---|---|
| Post-embolization syndrome (fatigue, fever, nausea) | Very common (~70โ80%) | Days 1โ14 | Grade 1โ2 (mild-moderate) | Supportive โ rest, paracetamol, antiemetics, hydration |
| Right upper quadrant pain / discomfort | Common (~40โ60%) | Days 1โ7 | Grade 1โ2 | Simple analgesia (paracetamol, NSAIDs if tolerated) |
| Transient liver enzyme elevation (AST/ALT/bilirubin) | Common (~50โ70%) | Weeks 1โ4 | Grade 1โ2 (self-limiting) | Monitor โ usually resolves spontaneously |
| Radiation-induced liver disease (REILD) | Uncommon (~3โ10%) | Weeks 4โ8 | Grade 3โ4 (serious) | Corticosteroids (dexamethasone); supportive care; specialist hepatology review |
| Radiation pneumonitis | Rare (<2%) when LSF properly assessed | Weeks 4โ12 | Grade 2โ4 | High-dose corticosteroids; if severe, bronchodilators and supportive care |
| Radiation gastritis / duodenal ulceration | Rare (<2%) with proper workup | Weeks 4โ12 | Grade 2โ3 | PPI therapy; endoscopic management if bleeding |
| Cholecystitis | Uncommon (~5%) if cystic artery not protected | Weeks 1โ4 | Grade 2โ3 | Conservative management; cholecystectomy in selected cases |
| Hepatic abscess | Rare (<1%) | Weeks 2โ8 | Grade 3 | Antibiotics ยฑ drainage; higher risk in patients with prior biliary manipulation |
| Post-TARE biliary stricture | Rare (< 3%) | Months 1โ6 | Grade 2โ3 | Biliary drainage (ERCP/PTC); MRCP surveillance |
Radiation-Induced Liver Disease (REILD) โ Recognition and Management
REILD is the most important TARE complication for patients to understand โ it is serious but treatable when recognised early. This step-by-step guide covers how it develops, how to recognise it, and what happens when it is treated.
- 1
What Is REILD?
Radiation-induced liver disease is a syndrome of liver dysfunction that develops 4โ8 weeks after TARE when the mean absorbed radiation dose to non-tumorous liver exceeds the hepatic radiation tolerance threshold (typically >70 Gy for non-cirrhotic, >50 Gy for cirrhotic liver). It represents radiation hepatitis โ inflammation and congestion of the liver parenchyma outside the treated tumour zone.
- 2
Signs and Symptoms of REILD
REILD typically presents with: new or worsening jaundice (yellow skin/eyes), new ascites (abdominal distension from fluid accumulation), marked fatigue, elevated bilirubin and alkaline phosphatase on blood tests, and right upper quadrant discomfort. Fever is less prominent than in early post-procedural syndrome.
- 3
Distinguishing REILD From Tumour Progression
REILD and hepatic decompensation from tumour progression can present similarly. REILD is confirmed by liver biopsy (congestion + veno-occlusive change in non-tumorous liver) or by clinical diagnosis on MRI/CT showing diffuse non-tumorous liver changes without new tumour growth. Distinguishing the two is important because the management approaches differ.
- 4
Treatment of REILD โ Corticosteroids Are Key
The primary treatment for established REILD is high-dose corticosteroids (typically dexamethasone 8โ12 mg/day or methylprednisolone, tapered over 4โ8 weeks) to suppress hepatic radiation inflammation and reduce veno-occlusive congestion. Early treatment โ before jaundice becomes severe โ dramatically improves outcomes. Severe or refractory REILD may require defibrotide (used for hepatic veno-occlusive disease) or specialist hepatology management.',
- 5
Prevention โ Personalised Dosimetry
REILD is largely preventable with proper dosimetric planning: keeping mean non-tumorous liver absorbed dose below the tolerance threshold using the partition model. This is why personalised dosimetry is not optional โ it is the primary tool for preventing the most serious TARE complication. CancerFax ensures treatment is coordinated at centres performing partition model dosimetry.
Prevention vs Management โ The TARE Safety Framework
Most serious TARE complications are preventable. The safety framework operates at two levels: prevention (pre-treatment workup and dosimetry) and early recognition (post-treatment monitoring).
Prevention โ Before Treatment
- MAA scan and lung shunt fractionMandatory pre-treatment โ identifies patients at risk of radiation pneumonitis from pulmonary microsphere shunting, allowing activity reduction or contraindication before treatment.
- Aberrant vessel coil embolization at mappingGastric, duodenal, and cystic arteries identified and coiled during the mapping session โ preventing GI ulceration and cholecystitis during actual treatment.
- Personalised partition model dosimetryCalculating the absorbed dose to non-tumorous liver before ordering activity โ ensuring the REILD dose threshold is not exceeded while achieving therapeutic tumour dose.
- Strict liver function eligibility criteriaChild-Pugh A and bilirubin < 2 mg/dL requirements filter out patients whose liver reserve is too compromised to tolerate any further radiation injury.
Early Recognition โ After Treatment
- Post-TARE liver function monitoring at 4 and 8 weeksBlood tests (bilirubin, AST/ALT, ALP, INR) at 4 and 8 weeks post-TARE are mandatory โ REILD onset at this window requires early biochemical detection before clinical decompensation.
- Patient education on REILD symptomsPatients and families must know to report new jaundice, abdominal swelling, or marked fatigue at 4โ8 weeks โ these symptoms require same-day or next-day clinical assessment.
- Immediate access to treating centre if symptoms developPatients treated abroad or at distant centres must have a clear escalation pathway โ CancerFax provides a direct contact route to the treating team for any post-TARE clinical concern.
- Corticosteroid treatment within 24โ48 hours of REILD diagnosisEarly corticosteroid initiation before bilirubin exceeds 10 mg/dL is associated with significantly better REILD outcomes than delayed treatment.
TARE Complications โ Key Numbers
Quantitative reference points for the incidence and severity of major TARE complications.
- ~3โ10%Incidence of clinically significant REILD in published TARE seriesRisk is higher in cirrhotic patients and those receiving higher total liver doses โ largely mitigated by partition model dosimetry at specialist centres.
- 4โ8 weeksTypical onset window for REILD after TAREAll TARE patients must have liver function tests at 4 weeks and 8 weeks post-treatment โ the surveillance window where REILD must be caught early.
- <2%Incidence of radiation pneumonitis when MAA scan workup is correctRadiation pneumonitis is effectively prevented by proper lung shunt fraction assessment and activity adjustment โ an almost entirely preventable complication.
More from the TARE / Y-90 Resource Library
Continue exploring TARE โ from treatment day and radiation safety to the complete evidence guides and workup.
Frequently Asked Questions About TARE Complications
I have jaundice and swollen abdomen 6 weeks after TARE. What should I do?
These symptoms โ new jaundice and ascites at 6 weeks post-TARE โ are the classic presentation of radiation-induced liver disease (REILD) and require urgent same-day medical assessment. Contact your treating team or nearest emergency department immediately. Do not wait for a scheduled follow-up appointment. Early corticosteroid treatment dramatically improves REILD outcomes โ delay in diagnosis and treatment significantly worsens prognosis. If you are in your home country after treatment abroad, CancerFax provides an emergency escalation route to the treating team in China or India โ contact us and we will connect you with the clinical team within hours.
How do I know if my centre is using personalised dosimetry to prevent REILD?
Ask your interventional radiologist directly: 'Are you using the partition model for my dosimetry, and what is the estimated absorbed dose in Gray to my non-tumorous liver?' A centre using personalised dosimetry will be able to provide a numerical Gy estimate for both tumour and normal liver. If your centre is using only the BSA (body surface area) method or an empirical lookup table without individualised Gy calculations, the normal liver dose is not being directly monitored โ increasing REILD risk. CancerFax specifically coordinates with centres in China and India that perform partition model dosimetry as standard practice.
Can the GI complications (gastritis, ulceration) be prevented?
Yes โ GI complications from non-target microsphere deposition into gastric or duodenal arteries are almost entirely preventable by thorough aberrant vessel identification and coil embolization at the mapping session. If the mapping arteriogram identifies gastric, right gastric, right gastroepiploic, or other GI-feeding branches arising from the hepatic arterial territory, these should be prophylactically coiled before the treatment session. Patients at higher risk (prior upper GI surgery, anatomical variants) should receive proton pump inhibitor (PPI) therapy for 2โ4 weeks after TARE as an additional precaution regardless of coiling status.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Concerned About TARE Complications or Eligibility?
CancerFax reviews your liver function and prior treatment history to assess TARE eligibility and ensures treatment is coordinated at centres with personalised dosimetry โ the most effective tool for preventing REILD.
This content is for informational purposes only and does not constitute medical advice. Always seek immediate medical attention for any new or worsening symptoms after TARE.